167 related articles for article (PubMed ID: 17510448)
1. Ximelagatran versus warfarin in the prevention of atrial fibrillation-related stroke: both sides of the story.
Testa L; Van Gaal W; Agostoni P; Abbate A; Trotta G; Biondi-Zoccai GG
Stroke; 2007 Jul; 38(7):e57. PubMed ID: 17510448
[No Abstract] [Full Text] [Related]
2. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Selçuk H; Selçuk MT; Maden O
Anadolu Kardiyol Derg; 2007 Mar; 7(1):54-8. PubMed ID: 17347079
[TBL] [Abstract][Full Text] [Related]
3. Secondary stroke prevention with ximelagatran versus warfarin in patients with atrial fibrillation: pooled analysis of SPORTIF III and V clinical trials.
Akins PT; Feldman HA; Zoble RG; Newman D; Spitzer SG; Diener HC; Albers GW
Stroke; 2007 Mar; 38(3):874-80. PubMed ID: 17255547
[TBL] [Abstract][Full Text] [Related]
4. Ximelagatran or warfarin for stroke prevention in patients with atrial fibrillation?
Hankey GJ; Klijn CJ; Eikelboom JW
Stroke; 2004 Feb; 35(2):389-91. PubMed ID: 14757889
[No Abstract] [Full Text] [Related]
5. Effect of ximelagatran and warfarin on stroke subtypes in atrial fibrillation.
Teitelbaum JS; von Kummer R; Gjesdal K; Kristinsson A; Gahn G; Albers GW;
Can J Neurol Sci; 2008 May; 35(2):160-5. PubMed ID: 18574928
[TBL] [Abstract][Full Text] [Related]
6. [Ximelagatran cannot be an alternative to standard warfarin therapy in chronic atrial fibrillation/ antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Cavuşoğlu Y
Anadolu Kardiyol Derg; 2007 Jun; 7(2):217-8; author reply 218-9. PubMed ID: 17513231
[No Abstract] [Full Text] [Related]
7. Costs and effectiveness of ximelagatran for stroke prophylaxis in chronic atrial fibrillation.
O'Brien CL; Gage BF
JAMA; 2005 Feb; 293(6):699-706. PubMed ID: 15701911
[TBL] [Abstract][Full Text] [Related]
8. Ximelagatran for stroke prevention in atrial fibrillation.
Boos CJ; Lip GY
Expert Rev Cardiovasc Ther; 2005 Jul; 3(4):551-63. PubMed ID: 16076267
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of ximelagatran for stroke prevention.
Perret-Guillaume C; Wahl D
JAMA; 2005 Jun; 293(23):2860-1; author reply 2861. PubMed ID: 15956626
[No Abstract] [Full Text] [Related]
10. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Tandoğan I
Anadolu Kardiyol Derg; 2007 Jun; 7(2):216; author reply 218-9. PubMed ID: 17513230
[No Abstract] [Full Text] [Related]
11. [Antithrombotic therapy in atrial fibrillation with ximelagatran: can it be an alternative to warfarin?].
Kiraç FS
Anadolu Kardiyol Derg; 2007 Jun; 7(2):214-5; author reply 218-9. PubMed ID: 17513229
[No Abstract] [Full Text] [Related]
12. Does warfarin for stroke thromboprophylaxis protect against MI in atrial fibrillation patients?
Lip GY; Lane DA
Am J Med; 2010 Sep; 123(9):785-9. PubMed ID: 20655037
[TBL] [Abstract][Full Text] [Related]
13. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study.
Petersen P; Grind M; Adler J;
J Am Coll Cardiol; 2003 May; 41(9):1445-51. PubMed ID: 12742279
[TBL] [Abstract][Full Text] [Related]
14. Preventing stroke in atrial fibrillation: the SPORTIF programme.
Lip GY
Pathophysiol Haemost Thromb; 2005; 34 Suppl 1():25-30. PubMed ID: 15812201
[TBL] [Abstract][Full Text] [Related]
15. Stroke prevention in atrial fibrillation: anticoagulants and antithrombotics.
Ezekowitz MD
Am Heart Hosp J; 2004; 2(4 Suppl 1):31-5. PubMed ID: 15539973
[TBL] [Abstract][Full Text] [Related]
16. Comparison of bleeding in patients with nonvalvular atrial fibrillation treated with ximelagatran or warfarin: assessment of incidence, case-fatality rate, time course and sites of bleeding, and risk factors for bleeding.
Douketis JD; Arneklev K; Goldhaber SZ; Spandorfer J; Halperin F; Horrow J
Arch Intern Med; 2006 Apr; 166(8):853-9. PubMed ID: 16636210
[TBL] [Abstract][Full Text] [Related]
17. Stroke prevention using the oral direct thrombin inhibitor ximelagatran in patients with non-valvular atrial fibrillation. Pooled analysis from the SPORTIF III and V studies.
Diener HC;
Cerebrovasc Dis; 2006; 21(4):279-93. PubMed ID: 16449807
[TBL] [Abstract][Full Text] [Related]
18. Ximelagatran or warfarin in atrial fibrillation?
Epstein EF
Lancet; 2004 Feb; 363(9410):736; author reply 736. PubMed ID: 15001338
[No Abstract] [Full Text] [Related]
19. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): randomised controlled trial.
Olsson SB;
Lancet; 2003 Nov; 362(9397):1691-8. PubMed ID: 14643116
[TBL] [Abstract][Full Text] [Related]
20. Ximelagatran or warfarin in atrial fibrillation?
MacAllister R; Hingorani AD; Casas JP
Lancet; 2004 Feb; 363(9410):735-6; author reply 736. PubMed ID: 15001337
[No Abstract] [Full Text] [Related]
[Next] [New Search]
